The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 27, 2015
Filed:
Mar. 15, 2005
Young-choon Moon, Belle Mead, NJ (US);
Liangxian Cao, Parlin, NJ (US);
Nadarajan Tamilarasu, Edison, NJ (US);
Hongyan Qi, Plainsboro, NJ (US);
Soongyu Choi, Skillman, NJ (US);
William Joseph Lennox, South Plainfield, NJ (US);
Donald Thomas Corson, Annandale, NJ (US);
Young-Choon Moon, Belle Mead, NJ (US);
Liangxian Cao, Parlin, NJ (US);
Nadarajan Tamilarasu, Edison, NJ (US);
Hongyan Qi, Plainsboro, NJ (US);
Soongyu Choi, Skillman, NJ (US);
William Joseph Lennox, South Plainfield, NJ (US);
Donald Thomas Corson, Annandale, NJ (US);
PTC Therapeutics, Inc., South Plainfield, NJ (US);
Abstract
In accordance with the present invention, tetracyclic caboline derivatives that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, these compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.